Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28022736 | 1.00 | ACE (0.31) | ACEGRM2GRM3 | |
| SCHEMBL15114474 | 0.81 | TSHR (0.38) | — | |
| SCHEMBL3512916 | 0.80 | GRM2 (0.36) | GRM2GRM3 | |
| SCHEMBL6919995 | 0.80 | GRM2 (0.36) | GRM2GRM3 | |
| SCHEMBL4254372 | 0.80 | GRM2 (0.36) | GRM2GRM3 | |
| SCHEMBL2026722 | 0.78 | — | — | |
| SCHEMBL2023665 | 0.78 | CHRM2 (0.31) | — | |
| SCHEMBL22518862 | 0.78 | CYP2C19 (0.33) | GRM2GRM3 | |
| SCHEMBL22518863 | 0.78 | CYP2C19 (0.33) | GRM2GRM3 | |
| SCHEMBL10215476 | 0.77 | HSD17B10 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248949-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-02-17 | — | — | CN | disclosed |
| US-11154563-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3571208-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-11-07 | — | — | US | disclosed |
| WO-2018136401-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154563-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | ACE 128/4885GRM2 4115/4885GRM3 4640/4885 |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | ACE 128/4885GRM2 4115/4885GRM3 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.